Postpartum Depression in Black Mothers

Postpartum depression (PPD) affects roughly 1 in 7 mothers in the United States, but Black mothers face this at disproportionate rates, are less likely to be screened, and are significantly less likely to receive treatment. In a country where Black women already face a maternal mortality crisis, untreated PPD is not a side issue -- it is a public health emergency. This page explains what postpartum depression looks like for Black mothers, why the rates are higher, and what treatment options are available, including a medication approved by the FDA specifically for PPD.

• Persistent low mood, emptiness, or numbness lasting more than two weeks after birth
• Irritability, anger, or rage that feels disproportionate to the trigger
• Loss of interest in the baby, in things you used to enjoy, or in sex
• Sleep disturbance beyond newborn-driven sleep loss (cannot sleep when baby sleeps, or sleeping excessively)
• Appetite changes, unintended weight loss or gain
• Fatigue that does not improve with rest
• Difficulty bonding with the baby, feeling like a stranger to your own child
• Intrusive thoughts about harm coming to the baby (common in PPD and treatable; distinct from postpartum psychosis)
• Excessive guilt, worthlessness, or the sense that the baby would be better off without you
• Trouble concentrating, making decisions, or remembering things
• Physical complaints without clear cause: headaches, gut symptoms, chest tightness
• Thoughts of suicide or of not wanting to be alive

ACOG (CPG #4, June 2023, PMID 37486660) and USPSTF (2019) both recommend universal screening for depression at least once during pregnancy and again in the postpartum period, with the postpartum visit no later than 12 weeks after delivery. The two most common instruments are the Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-report with a standard cutoff of 10 or higher (13 in some protocols), and the Patient Health Questionnaire-9 (PHQ-9), a 9-item depression screener with a standard cutoff of 10.

Both tools were developed and validated in predominantly white samples. In Black perinatal populations, two issues recur:

• Standard cutoffs under-detect. Tandon et al. (2012, PMID 21864914) tested the EPDS, CES-D, and BDI-II in 95 low-income African American perinatal women and found sensitivity improved substantially when cutoffs were lowered below the manufacturer-recommended thresholds. Chaudron et al. (2010, PMID 20156899) reached a similar conclusion in low-income urban mothers.
• Cultural framing of items. Questions about "crying" and "feeling sad" map poorly onto a presentation dominated by irritability, somatic symptoms, and stoicism.

A negative screen in a Black mother who is clearly struggling is not the end of the conversation. ACOG explicitly calls for clinical judgment alongside the score and for follow-up screening across the postpartum year, because symptoms can emerge or escalate months after delivery.

Postpartum depression is treatable, and most mothers improve with appropriate care. Treatment selection depends on severity, breastfeeding status, prior treatment response, and patient preference.

• Psychotherapy. Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) have the strongest evidence for mild-to-moderate PPD, and USPSTF’s 2019 perinatal depression preventive intervention recommendation specifically endorses counseling interventions. For Black mothers, finding a culturally responsive clinician is not a luxury; it materially affects whether treatment is started and continued.
• SSRIs (selective serotonin reuptake inhibitors). Sertraline (Zoloft) is the first-line SSRI in lactation because it has the most data and the lowest infant exposure through breast milk. Other options include escitalopram and fluoxetine. SSRIs typically take 4 to 6 weeks for full effect.
• Brexanolone (Zulresso). FDA-approved in March 2019 as the first medication developed specifically for postpartum depression. Given as a 60-hour continuous IV infusion at a REMS-certified facility, with onset often within 24 to 48 hours. Restricted access and cost have limited real-world use.
• Zuranolone (Zurzuvae). FDA-approved on August 4, 2023 as the first oral medication for postpartum depression in adults. A once-daily 14-day course, with antidepressant effect reported as early as day 3 in clinical trials. A practical alternative to brexanolone for many patients, though access, insurance coverage, and breastfeeding data should be discussed with the prescriber.
• Combination care. Moderate-to-severe PPD typically responds best to medication plus therapy, with social support (peer groups, paid leave use, lactation support, sleep protection) as a non-optional layer of treatment, not a substitute for it.
• Severe or psychotic presentations. Inpatient psychiatric care, ECT in select cases, and immediate separation of any postpartum psychosis from the depression diagnosis. Postpartum psychosis carries a meaningfully elevated suicide and infanticide risk and is an emergency.